
ERS Genomics
ERS Genomics was formed to commercialize the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. The team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development.
Latest ERS Genomics Content

ERS Genomics and Université De Montréal Sign CRISPR/Cas9 License Agreement

ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement

ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement

Ers Genomics and StemSight Sign CRISPR/Cas9 License Agreement

Key Charpentier/Doudna CRISPR Patent Upheld by Japanese Patent Office

How CRISPR Is Transforming High-Throughput Screening

ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

What’s Hot in Synthetic Biology Right Now?

New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge
